The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

More Than 100 Presentations and Posters Evaluating Celgene Products to Be Highlighted at Three Major Medical Meetings in June

Friday, May 21, 2010

More Than 100 Presentations and Posters Evaluating Celgene Products to Be Highlighted at Three Major Medical Meetings in June07:30 EDT Friday, May 21, 2010 BOUDRY, Switzerland (Business Wire) -- Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials evaluating Celgene products in blood cancers and solid tumors at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois from June 4-8. Additionally, clinical data will be presented on Celgene products in blood cancers at the International Myeloma Working Group Summit in Barcelona, Spain from June 8-9 and the European Hematology Association annual meeting in Barcelona, Spain from June 10-13. About Celgene International Sàrl Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.